Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19922264 | 1.00 | KMT2A (0.37) | KMT2AHTTSMN1; SMN2TDP1MAPK1 | |
| SCHEMBL19930018 | 1.00 | KMT2A (0.37) | KMT2AHTTSMN1; SMN2TDP1MAPK1 | |
| Iodide SCHEMBL31003066 | 0.80 | HTR1F (0.39) | KMT2ASMN1; SMN2TDP1L3MBTL1MEN1 | |
| SCHEMBL11220519 | 0.79 | MAPK1 (0.34) | KMT2AHTTSMN1; SMN2TDP1MAPK1 | |
| SCHEMBL11220517 | 0.79 | MAPK1 (0.34) | KMT2AHTTSMN1; SMN2TDP1MAPK1 | |
| SCHEMBL27098597 | 0.78 | KMT2A (0.40) | KMT2AHTTSMN1; SMN2TDP1MAPK1 | |
| SCHEMBL20766727 | 0.78 | KMT2A (0.42) | KMT2AHTTSMN1; SMN2TDP1MAPK1 | |
| SCHEMBL9763497 | 0.72 | KMT2A (0.43) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL19883160 | 0.72 | KMT2A (0.43) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL25128746 | 0.72 | KMT2A (0.37) | KMT2AHTTSMN1; SMN2TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| EP-3506913-A1 | TARGETING LIGANDS | Arrowhead Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10294474-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294474-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | KMT2A 4229/4885HTT 2695/4885SMN1; SMN2 3429/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | KMT2A 4229/4885HTT 2695/4885SMN1; SMN2 3429/4885 |
| US-10294474-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | KMT2A 4229/4885HTT 2695/4885SMN1; SMN2 3429/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | KMT2A 4229/4885HTT 2695/4885SMN1; SMN2 3429/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | KMT2A 4229/4885HTT 2695/4885SMN1; SMN2 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.